Blurbs

Forma Therapeutics Holdings (FMTX) Receives a Buy from SVB Securities

In a report issued on August 3, Andrew Berens from SVB Securities maintained a Buy rating on Forma Therapeutics Holdings (FMTXResearch Report). The company’s shares closed last Thursday at $9.84.

According to TipRanks.com, Berens ‘ ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -5.0% and a 45.4% success rate. Berens covers the Healthcare sector, focusing on stocks such as Turning Point Therapeutics, Theseus Pharmaceuticals, and Compass Therapeutics.

Forma Therapeutics Holdings has an analyst consensus of Strong Buy, with a price target consensus of $35.00.

See Insiders’ Hot Stocks on TipRanks >>

Forma Therapeutics Holdings’ market cap is currently $431.2M and has a P/E ratio of -2.36.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Forma Therapeutics Holdings Inc is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of novel therapeutics to transform the lives of patients with rare hematologic diseases and cancers. The firm’s pipeline products are FT-4202, FT-7051, FT-8225, and others.

Read More on FMTX:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos